New Delhi: Indian Immunologicals Limited (IIL), one of India’s leading vaccine manufacturers, has refuted claims by Australian health authorities over fake doses of its antirabies vaccine Abhayrab in India.
In a statement, IIL issued a clarification regarding the alert issued by the Australian Technical Advisory Group on the circulation of counterfeit batches of vaccine since November 2023.
“In January 2025, IIL proactively identified in the market one specific batch (Batch # KA 24014) with a packaging different to the original. The company immediately notified Indian regulators and law enforcement agencies, lodged a formal complaint, and worked closely with authorities t o ensure swift action. Importantly, this was a n isolated incident. The Abhayrab batch KA24014 manufactured and distributed across variousregions of India through IIL’s authorised distribution channels and NO market complaints were reported in relation to this batch. This goes on to affirm the quality and efficacy of’ IIL’s vaccine, when procured from its authorised channels. There’s no instance o f any other counterfeit batch in the market beyond Batch No. KA24014.”
“Reassuring healthcare professionals and the public, IIL emphasized that every batch of vaccine manufactured in India is tested and released by the Central Drugs Laboratory (Government o f India) before being made available for sale o r administration. Supplies made through government institutions and authorized distributors remain safe and of standard quality. Sunil Tiwari, Vice President & Head of Quality Management at IIL, stated that IIL aims to reassure stakeholders that the company’s pharmacovigilance and quality systems are robust, and that the public.”
